Investor Presentaiton
OmnImmune Case Histories
TC
BIOPHARM
Omnimmune (TCB002) - a single dose leads to marked AML blast reduction (bone marrow)
in relapsed/refractory AML patients
8 individuals enrolled all with poor life expectancy (often days/weeks), 7 of whom received Omnlmmune
Patients PRA1-5001, 5004 and 5005 were screening failures, patient PRA1-5003 died 21 days post-treatment, patient PRA1-5010 was
withdrawn because of COVID pandemic before follow-up bone marrow aspirate and patient PRA1-5011 was withdrawn before
Omnimmune treatment due to COVID pandemic
Baseline high blast counts, and all patients had progressive/aggressive disease
All prior clinical options have failed (4th line of treatment)
Initial Dose
PRA1-5002
1x106 cells/kg
(total dose 6.1 x 107)
Blast cell reduction:
PRA1-5006
1x106 cells/kg
(total dose 7.0 x 107)
Blast cell reduction:
62.8% at baseline
51.2% at baseline
Preliminary
28.5% 14 days post-treat
8.4% 14 days post-treat
Data
10% on D28
(STABLE DISEASE)
2.6% on D28
(MLFS)***
PRA1-5007*
1x107 cells/kg
(total dose 7 x 108)
Blast cell reduction:
9.0% at baseline
4.6% 14 days post-treat
3.6% on D28
(COMPLETE RESPONSE)
PRA1-5008
1x107 cells/kg
(total dose 6.5 x 108)
Blast cell reduction:
14.8% at baseline
6.9% 14 days post-treat**
Disease progression
PRA1-5009
1x107 cells/kg
(total dose 8.5 x 108)
Blast cell reduction:
66.6% at baseline
38.0% 14 days post-treat
Study discontinued
due to COVID
* PRA1-5007 was 4th line of treatment, relapsed refractory with low-blast count AML (LBC-AML). Counts shown in bone marrow - peripheral blood blast count was 2.5% on
treatment, 0% at day 14 and D28. Patient PRA1-5007 achieved complete remission by D28.
** Peripheral blood (not bone marrow).
*** MLFS: morphologic leukemia-free state
20
20View entire presentation